MHRA licenses two jet-lag treatments
The medicines can now satisfy a previously unmet clinical need, in an area where where patient demand is high.
Read More
Tag: marketing authorisations
EMA’s PRAC to review Xeljanz and recommends fenspiride withdrawl
The committee has announced its latest meeting highlights.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
